Novel Biomarkers in Leukemia: From Benchtop to Bedside
A special issue of Diagnostics (ISSN 2075-4418). This special issue belongs to the section "Pathology and Molecular Diagnostics".
Deadline for manuscript submissions: closed (30 September 2022) | Viewed by 1996
Special Issue Editors
Interests: flow cytometry; experimental hematology; cellular therapy; hemopoiesis; leukemia diagnosis
Special Issues, Collections and Topics in MDPI journals
Interests: protein structure–function; molecular dynamics; computational biology; structural biology; molecular basis of diseases; biophysics
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Leukemia is a highly heterogeneous disease caused by the malignant transformation of undifferentiated myeloid/lymphoid hematopoietic progenitors. Leukemia subtypes are usually distinguished by considering the white cells affected (lymphoid or myeloid) and by the timescale of the disease development (acute or chronic). Despite this classification, a significant degree of heterogeneity is detected even within each leukemia subtype. It is also important to note that the precise molecular mechanisms underlying these forms of disease are in most cases yet to be identified.
In this scenario, the identification of new leukemia biomarkers represents a crucial step for diagnosis, prognosis and treatment. Currently, cytogenetic markers are widely used for diagnosis and patient stratification. However, the situation is rapidly changing due to the application of other methodologies based on the characterization of disease-causing mutations and of epigenetic and proteomic profiles. In this Special Issue, we are inviting the submission of reviews and novel research results in the field. In this Special Issue, special attention will be given to manuscripts highlighting the interplay between the search for new biomarkers and the elucidation of the molecular basis of this widespread disease. Moreover, articles dealing with identifying surface antigens in leukemia to plan novel CAR-T-mediated cellular therapy will be welcome.
We are looking forward to and will be welcoming your contributions to this Issue.
Dr. Peppino Mirabelli
Dr. Luigi Vitagliano
Dr. Giovanni Smaldone
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- leukemia subtype classifications
- molecular bases of leukemia
- leukemia patient stratification
- biomarkers and prognosis
- theranostics
- CAR-T cells
